Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company focused on artificial intelligence (AI), went public in April ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning.

CEO Christopher Gibson was one of those sellers, with a Thursday reveal that he had sold 40,390 shares of Recursion's common stock. Chief R&D and commercial officer Najit Khan was also a seller; she ...

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...

AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence.

Recursion, a leader in AI-based drug development, has met the hype-or-hope challenge head-on, by going public since June with plans to announce clinical data from at least seven pipeline ...

Recursion’s study will initially address the recurrent C. diff (up to 175,000 cases in the US per year) population, which costs the healthcare system approximately US$2 billion per year. (US$1=RM4.32) ...